The use of combination immunotherapies as front-line therapy for non-small-cell lung cancer

被引：7
作者：
Santana-Davila, Rafael [1 ]
Chow, Laura Q. M. [1 ]
机构：
[1] Univ Washington, Dept Med, Div Med Oncol, Seattle, WA 98195 USA
来源：
FUTURE ONCOLOGY | 2018年 / 14卷 / 03期
关键词：
chemo-immunotherapy; first-line; immune checkpoint inhibitors; immunotherapy; lung cancer; NSCLC; treatment naive; PACLITAXEL PLUS CARBOPLATIN; OPEN-LABEL; PHASE-III; PEMBROLIZUMAB; NIVOLUMAB; DOCETAXEL; CHEMOTHERAPY; MULTICENTER; IPILIMUMAB;
D O I：
10.2217/fon-2017-0124
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：191 / 194
页数：4
相关论文
共 50 条
[41]   Neoadjuvant immunotherapy in non-small-cell lung cancer: a narrative review on mechanisms, efficacy and safety [J].
Shao, Lan ;
Lou, Guangyuan .
JOURNAL OF THORACIC DISEASE, 2022,
[42]   Serious adverse effects with immunotherapies for the treatment of melanoma, non-small cell lung cancer, and renal cell carcinoma: Real-world evidence study [J].
Cuenot, Lea ;
Valnet-Rabier, Marie-Blanche ;
Bendjama, Abdelmalek ;
Aubin, Francois ;
Fischer, Sarah ;
Viot, Julien ;
Nerich, Virginie .
BULLETIN DU CANCER, 2024, 111 (12) :1111-1121
[43]   Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small cell lung cancer [J].
Georgieva, Mina ;
da Silveira Nogueira Lima, Joao P. ;
Aguiar, Pedro ;
Lopes, Gilberto de Lima, Jr. ;
Haaland, Benjamin .
LUNG CANCER, 2018, 124 :248-254
[44]   First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with ImmuneCheckpoint Inhibitors [J].
Bylicki, Olivier ;
Barazzutti, Helene ;
Paleiron, Nicolas ;
Margery, Jacques ;
Assie, Jean-Baptiste ;
Chouaid, Christos .
BIODRUGS, 2019, 33 (02) :159-171
[45]   Effectiveness of first-line treatments in metastatic squamous non-small-cell lung cancer [J].
Levy, B. P. ;
Signorovitch, J. E. ;
Yang, H. ;
Patterson-Lomba, O. ;
Xiang, C. Q. ;
Parisi, M. .
CURRENT ONCOLOGY, 2019, 26 (03) :E300-E308
[46]   First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer [J].
Carbone, D. P. ;
Reck, M. ;
Paz-Ares, L. ;
Creelan, B. ;
Horn, L. ;
Steins, M. ;
Felip, E. ;
van den Heuvel, M. M. ;
Ciuleanu, T. -E. ;
Badin, F. ;
Ready, N. ;
Hiltermann, T. J. N. ;
Nair, S. ;
Juergens, R. ;
Peters, S. ;
Minenza, E. ;
Wrangle, J. M. ;
Rodriguez-Abreu, D. ;
Borghaei, H. ;
Blumenschein, G. R. ;
Villaruz, L. C. ;
Havel, L. ;
Krejci, J. ;
Corral Jaime, J. ;
Chang, H. ;
Geese, W. J. ;
Bhagavatheeswaran, P. ;
Chen, A. C. ;
Socinski, M. A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (25) :2415-2426
[47]   Immunotherapy of non-small-cell lung cancer [J].
Reinmuth, Niels ;
Merk, Martina ;
Duell, Thomas .
ONKOLOGE, 2021, 27 (02) :179-190
[48]   Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology [J].
Mithoowani, Hamid ;
Febbraro, Michela .
CURRENT ONCOLOGY, 2022, 29 (03) :1828-1839
[49]   Adjuvant and Neoadjuvant Immunotherapy in Non - small Cell Lung Cancer [J].
Broderick, Stephen R. .
THORACIC SURGERY CLINICS, 2020, 30 (02) :215-+
[50]   Treatment of non-small-cell lung cancer after progression on nivolumab or pembrolizumab [J].
Freeman, A. T. ;
Lesperance, M. ;
Wai, E. S. ;
Croteau, N. S. ;
Fiorino, L. ;
Geller, G. ;
Brooks, E. G. ;
Poonja, Z. ;
Fenton, D. ;
Irons, S. ;
Ksienski, D. .
CURRENT ONCOLOGY, 2020, 27 (02) :76-82
12345